📰 Gracell Bio News
Gracell Bio News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Gracell Bio. Real-time updates on events, politics, business and more.
December 26, 2023
The cash deal, which adds several experimental therapies to AstraZenecas portfolio, values Gracell at $2 per ordinary share, or $10 per ADS of Gracell, plus a non-tradable contingent value right of $0.30 per ordinary share, if certain regulatory milestones are met.
May 12, 2023
DUBLIN--(BUSINESS WIRE)--The "CAR T - Cell Therapy - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 250+ companies and 500+ drugs in CAR T - Cell Therapy Competitive landscape. It covers the therapeutics assessment by product...
December 15, 2022
/PRNewswire/ -- The "China Cell Therapy Market Opportunity & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.coms offering. China...
December 15, 2022
/PRNewswire/ -- The "China Cell Therapy Market Opportunity & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.coms offering. China...
December 9, 2022
DUBLIN--(BUSINESS WIRE)--The "China Cell Therapy Market Opportunity & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.China has emerged as one of the world's largest pharmaceutical markets as a result of a exponential rise in clinical research and development activity in rece...